WinstonWınston
Boiron S.A. logo

Boiron S.A.

BOI.PA
63
Drug Manufacturers - Specialty & Generic · Healthcare
Also trades as: 0DTF.L
Price
€26.50
+0.40 (+1.53%)
Market Cap
€460.1M
Exchange
Euronext Paris
Winston Score
63
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 12, 2026 · filings through Dec 31, 2025

Boiron is a French pharmaceutical company that makes homeopathic medicines — products made from highly diluted natural substances like plants and minerals. Its best-known product is Oscillococcinum, a remedy marketed for flu-like symptoms, sold in pharmacies across dozens of countries. Boiron is the world's largest manufacturer of homeopathic medicines.

The company sells its products directly to pharmacies and healthcare distributors, earning revenue through product sales rather than subscriptions or licensing. It operates primarily in France and Western Europe, with a growing presence in the United States and other international markets. The main risk Boiron faces is scientific and regulatory pressure — health authorities in several countries have questioned whether homeopathic products work better than placebos, and some governments have reduced or eliminated reimbursement for these medicines, which could shrink demand over time.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-1.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+163.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$6M/ year

Declining (-10% vs prior year)

1.1% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

83.5%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$98M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Boiron S.A.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.2% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 17.5M (2021) → 17.5M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
72.3%
Premium pricing power — 72.3% gross margin
Operating Margin
7.8%
Modest — 7.8% operating margin
ROCE
4.9%
Weak — 4.9% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+2.8%
Nearly flat sales (+2.8% YoY)
EPS YoY
+186.2%
Earnings growing fast (+186.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
170%
Turns 170% of profit into real cash
FCF Margin
8.0%
Modest free cash flow (8.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.03
Conservative — low debt load (0.03)
Interest Cover
20.84x
Comfortably covers interest (20.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
14.2x
Attractive valuation — P/E 14.2

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
+0.7
GROWING
Earnings roughly flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
4.84%
Healthy income — 4.84% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend Growth
+247.8%
Dividend growing fast (247.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial